{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["139(16)"],"submitter":["Craven B"],"pubmed_abstract":["The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% o"],"journal":["Blood"],"pagination":["2553-2560"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8912978"],"repository":["biostudies-literature"],"pubmed_title":["Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis."],"pmcid":["PMC8912978"],"pubmed_authors":["Lester W","Craven B","Pavord S","Chudakou P","Singh D","Makris M","Scully M","Thomas W","Calvert A","Boyce S","Davies C","Kanny A","Hermans J","Bart-Smith E","Arnott S","Hunt BJ"],"additional_accession":[]},"is_claimable":false,"name":"Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.","description":"The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-04T08:24:22.269Z","creation":"2025-04-04T08:24:22.269Z"},"accession":"S-EPMC8912978","cross_references":{"pubmed":["35263420"],"doi":["10.1182/blood.2021014684"]}}